Logo image of AYLA

AYALA PHARMACEUTICALS INC (AYLA) Stock Fundamental Analysis

NASDAQ:AYLA - Nasdaq - US05465V1089 - Common Stock - Currency: USD

0.5036  +0.03 (+5.84%)

Fundamental Rating

2

Overall AYLA gets a fundamental rating of 2 out of 10. We evaluated AYLA against 559 industry peers in the Biotechnology industry. The financial health of AYLA is average, but there are quite some concerns on its profitability. AYLA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AYLA has reported negative net income.
AYLA had a negative operating cash flow in the past year.
AYLA Yearly Net Income VS EBIT VS OCF VS FCFAYLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

AYLA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AYLA Yearly ROA, ROE, ROICAYLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of AYLA (5.19%) is better than 74.49% of its industry peers.
AYLA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AYLA Yearly Profit, Operating, Gross MarginsAYLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

AYLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AYLA has more shares outstanding
There is no outstanding debt for AYLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AYLA Yearly Shares OutstandingAYLA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2M 4M 6M 8M 10M
AYLA Yearly Total Debt VS Total AssetsAYLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

AYLA has an Altman-Z score of -20.92. This is a bad value and indicates that AYLA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -20.92, AYLA is not doing good in the industry: 90.14% of the companies in the same industry are doing better.
AYLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.92
ROIC/WACCN/A
WACC8.99%
AYLA Yearly LT Debt VS Equity VS FCFAYLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.28 indicates that AYLA has no problem at all paying its short term obligations.
The Current ratio of AYLA (2.28) is worse than 79.97% of its industry peers.
A Quick Ratio of 2.28 indicates that AYLA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.28, AYLA is not doing good in the industry: 77.93% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.28
AYLA Yearly Current Assets VS Current LiabilitesAYLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.10% over the past year.
The Revenue for AYLA has decreased by -48.36% in the past year. This is quite bad
EPS 1Y (TTM)13.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
Revenue 1Y (TTM)-48.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-85.44%

3.2 Future

AYLA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.08% yearly.
The Revenue is expected to decrease by -12.82% on average over the next years. This is quite bad
EPS Next Y3.59%
EPS Next 2Y8.3%
EPS Next 3Y-8.08%
EPS Next 5YN/A
Revenue Next Year-33.92%
Revenue Next 2Y-12.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

AYLA Yearly Revenue VS EstimatesAYLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 1M 2M 3M
AYLA Yearly EPS VS EstimatesAYLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AYLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AYLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AYLA Price Earnings VS Forward Price EarningsAYLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AYLA Per share dataAYLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A cheap valuation may be justified as AYLA's earnings are expected to decrease with -8.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.3%
EPS Next 3Y-8.08%

More info and screens

0

5. Dividend

5.1 Amount

AYLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AYALA PHARMACEUTICALS INC

NASDAQ:AYLA (1/18/2023, 8:00:01 PM)

0.5036

+0.03 (+5.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2022-11-03/amc
Earnings (Next)03-27 2023-03-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners22.37%
Ins Owner Change0%
Market Cap7.46M
Analysts77.78
Price Target12.24 (2330.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.08%
Min EPS beat(2)-30.98%
Max EPS beat(2)18.82%
EPS beat(4)2
Avg EPS beat(4)-3.67%
Min EPS beat(4)-30.98%
Max EPS beat(4)18.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-89.78%
Min Revenue beat(2)-93.96%
Max Revenue beat(2)-85.61%
Revenue beat(4)1
Avg Revenue beat(4)-40.87%
Min Revenue beat(4)-93.96%
Max Revenue beat(4)61.99%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.86%
PT rev (3m)6.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-42.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)15.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.31
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-2.52
EYN/A
EPS(NY)-2.34
Fwd EYN/A
FCF(TTM)-2.3
FCFYN/A
OCF(TTM)-2.3
OCFYN/A
SpS0.12
BVpS0.55
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 5.19%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 2.28
Altman-Z -20.92
F-Score4
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)305.81%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
EPS Next Y3.59%
EPS Next 2Y8.3%
EPS Next 3Y-8.08%
EPS Next 5YN/A
Revenue 1Y (TTM)-48.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-85.44%
Revenue Next Year-33.92%
Revenue Next 2Y-12.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.27%
OCF growth 3YN/A
OCF growth 5YN/A